Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Agenus Inc (AGEN)

NASDAQ
Currency in USD
Disclaimer
6.460
+0.690(+11.96%)
Closed
After Hours
6.800+0.340(+5.263%)

AGEN Comments

https://seekingalpha.com/article/4663512-agenus-2024-may-finally-be-year-major-turnaround
Trading idea - Entry point has to be over 1.7/61.80%
Very nice, is it now starting to go up
It looks like finished
phase1 was fair enough, lets see phase2, it should worth 2.2-2.6$
Why this sell off
Agenus has only 260 employees in the US, and recently posted 42 new US job listings. Looks like they are poised for growth. Anyone have additional insight?
Ive been in this stock since april. This is the time in biopharma where all the money is made investing. If you buy now, you should see at least a 40% gain before news of approval, or not from FDA in December on Bal 1881 for cervical cancer.
looks like the perfect time to buy
Good to buy guys?
https://ch.marketscreener.com/kurs/aktie/MORPHOSYS-AG-436425/news/COMPANY-TALK-J-J-nbsp-41-Prozent-Plus-mit-Morphosys-Wirkstoff-33013409/
why is this one dropping so much?  i know there are 15% short, but the prospects are phenomenal
IM ON IT ..... It is going to the roof auuuurrrr
in perfect condition/
??? Doesn't really make sense mate.
 I know. Its just a chart. But i hope their products will be good... approved..
really to entry It worth ?
thoughts?
loading on drops for longs
7062551455
52003
7062551455
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.